依洛尤单抗在高危他汀治疗患者中的疗效与安全性:低LDL-C及最大强度他汀亚组分析
结果显示,无论基线LDL-C水平或他汀强度如何,依洛尤单抗均一致降低主要终点风险,且未发现新的安全性问题。
要点
- 关键次要终点在两组分析中均呈相似降低,未发现重大安全性问题。
核心结论
- 在稳定动脉粥样硬化性心血管疾病患者中,无论基线LDL-C是否低于70 mg/dL或背景他汀是否为最大强度,依洛尤单抗降低心血管事件的效果一致。
主要发现
- 关键次要终点在两项分析中均呈相似降低,未发现重大安全性问题。
关键数值与推荐
- 主要疗效终点为心血管死亡、心肌梗死、卒中、不稳定性心绞痛住院或冠状动脉血运重建的复合终点。
- 次要疗效终点为心血管死亡、心肌梗死或卒中的复合终点。
临床怎么用
- 对于已接受最大强度他汀且基线LDL-C已低于70 mg/dL的稳定动脉粥样硬化性心血管疾病高危患者,依洛尤单抗仍可进一步降低心血管事件风险,支持在此类患者中考虑联合PCSK9抑制剂。
局限性
- 本研究为FOURIER试验的二次事后分析,低LDL-C亚组样本量较小(2034例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundaries would be beneficial is unknown. OBJECTIVE: To compare outcomes of evolocumab vs placebo in patients with stable atherosclerotic cardiovascular disease and a baseline LDL-C of less than 70 mg/dL and in those receiving background treatment with a maximal-potency statin. DESIGN, SETTING, AND PARTICIPANTS: This secondary ad hoc analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial compared randomized treatments in 2 subgroups of patients with stable atherosclerotic cardiovascular disease currently receiving statin. Patients were classified by a baseline LDL-C of less than 70 or at least 70 mg/dL and by statin intensity (maximal: atorvastatin calcium, 80 mg/d, or rosuvastatin, 40 mg/d; submaximal: all other dosages). Patients with baseline LDL of less than 70 mg/dL either had a final screening LDL-C of at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 100 mg/dL. Data were retrieved from 2013 to 2016 and analyzed in 2017 based on intention to treat. MAIN OUTCOMES AND MEASURES: The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The secondary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. Safety outcomes included adverse events and events of interest identified in the FOURIER trial. Interaction testing was used to assess the consistency of results in patients who did vs did not satisfy the above criteria. RESULTS: A total of 27 564 patients (75.4% men and 24.6% women; mean [SD] age, 62.5 [9.0] years) were included in the analysis. Of 2034 patients (7.4%) who had a baseline LDL-C of less than 70 mg/dL, evolocumab reduced the risk for the primary endpoint (hazard ratio [HR], 0.80; 95% CI, 0.60-1.07) to a similar degree as in the 25 529 patients who had baseline LDL-C of at least 70 mg/dL (HR 0.86; 95% CI, 0.79-0.92; P = .65 for interaction; 1 patient was missing baseline LDL-C data). Of 7533 patients (27.3%) receiving maximal-potency statins, evolocumab significantly reduced the primary endpoint (HR, 0.86; 95% CI, 0.75-0.98) to a similar degree as in the 20 031 patients not receiving a maximal-potency statin (HR, 0.85; 95% CI, 0.78-0.93; P = .88 for interaction). The key secondary endpoint was reduced to a similar degree in both analyses. No major safety concerns were identified. CONCLUSIONS AND RELEVANCE: Evolocumab was equally effective in reducing cardiovascular events in patients with stable atherosclerotic cardiovascular disease regardless of whether the baseline LDL-C was less than 70 or at least 70 mg/dL and whether the background statin was of maximal or submaximal potency.
引用
- Giugliano RP, Keech A, Murphy SA, et al. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 29117276. doi:10.1001/jamacardio.2017.3944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。